{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T07:31:58Z","timestamp":1792481518657,"version":"4.5.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.ijcard.2024.131819","type":"journal-article","created":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T12:41:58Z","timestamp":1706618518000},"page":"131819","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Novel anti-psoriasis agent-associated cardiotoxicity, analysis of the FDA adverse event reporting system (FAERS)"],"prefix":"10.1016","volume":"402","author":[{"given":"Zaki","family":"Al-Yafeai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manush","family":"Sondhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavya","family":"Vadlamudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Vyas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniyal","family":"Nadeem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Alawadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Carvajal-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Ghoweba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Ananthaneni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2024.131819_bb0005","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.743180","article-title":"The global, regional, and National Burden of psoriasis: results and insights from the global burden of disease 2019 study","volume":"8","author":"Damiani","year":"2021","journal-title":"Front. Med."},{"key":"10.1016\/j.ijcard.2024.131819_bb0010","series-title":"StatPearls","author":"Nair","year":"2023"},{"key":"10.1016\/j.ijcard.2024.131819_bb0015","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jaci.2017.07.004","article-title":"Psoriasis pathogenesis and the development of novel targeted immune therapies","volume":"140","author":"Hawkes","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"issue":"Suppl. 1","key":"10.1016\/j.ijcard.2024.131819_bb0025","first-page":"40","article-title":"Clinical presentation of psoriasis","volume":"59","author":"Ayala","year":"2007","journal-title":"Reumatismo."},{"key":"10.1016\/j.ijcard.2024.131819_bb0030","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1038\/jid.2013.149","article-title":"Incidence of cardiovascular disease in individuals with psoriasis: a systematic review and meta-analysis","volume":"133","author":"Samarasekera","year":"2013","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.ijcard.2024.131819_bb0035","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.113.000062","article-title":"Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies","volume":"2","author":"Armstrong","year":"2013","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.ijcard.2024.131819_bb0040","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.3390\/ijms21051690","article-title":"Efficacy and safety of biologics for psoriasis and psoriatic arthritis and their impact on comorbidities: a literature review","volume":"21","author":"Kamata","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ijcard.2024.131819_bb0045","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.3389\/fimmu.2018.01668","article-title":"Psoriasis, cardiovascular events, and biologics: lights and shadows","volume":"9","author":"Caiazzo","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijcard.2024.131819_bb0050","first-page":"659","article-title":"Psoriasis as a cardiovascular risk factor: updates and algorithmic approach","volume":"153","author":"Cozzani","year":"2018","journal-title":"G Ital Dermatol E Venereol Organo Uff Soc Ital Dermatol E Sifilogr."},{"key":"10.1016\/j.ijcard.2024.131819_bb0055","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1007\/s12325-020-01346-6","article-title":"Psoriasis and cardiovascular risk: a comprehensive review","volume":"37","author":"Masson","year":"2020","journal-title":"Adv. Ther."},{"key":"10.1016\/j.ijcard.2024.131819_bb0060","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics","volume":"80","author":"Menter","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.ijcard.2024.131819_bb0065","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.3390\/ijms18112427","article-title":"Treatment approaches to moderate to severe psoriasis","volume":"18","author":"Gisondi","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ijcard.2024.131819_bb0070","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1080\/14740338.2019.1614561","article-title":"A safety review of recent advancements in the treatment of psoriasis: analysis of clinical trial safety data","volume":"18","author":"Kolli","year":"2019","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.ijcard.2024.131819_bb0080","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.ijcard.2024.131819_bb0085","doi-asserted-by":"crossref","first-page":"903","DOI":"10.2147\/TCRM.S227880","article-title":"Tildrakizumab: an evidence-based review of its use in the treatment of moderate-to-severe chronic plaque psoriasis","volume":"16","author":"N\u00e4slund-Koch","year":"2020","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.ijcard.2024.131819_bb0090","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/bjd.19341","article-title":"Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial","volume":"184","author":"Warren","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.ijcard.2024.131819_bb0095","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/bjd.19866","article-title":"Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)","volume":"185","author":"Thaci","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.ijcard.2024.131819_bb0100","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s40744-022-00434-z","article-title":"Effect of Secukinumab on traditional cardiovascular risk factors and inflammatory biomarkers: post hoc analyses of pooled data across three indications","volume":"9","author":"Merola","year":"2022","journal-title":"Rheumatol Ther."},{"key":"10.1016\/j.ijcard.2024.131819_bb0105","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","article-title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2024.131819_bb0110","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3390\/ph15010095","article-title":"Secukinumab loss of efficacy is perfectly counteracted by the introduction of combination therapy (rescue therapy): data from a multicenter real-life study in a cohort of Italian psoriatic patients that avoided Secukinumab switching","volume":"15","author":"Damiani","year":"2022","journal-title":"Pharmaceuticals."},{"key":"10.1016\/j.ijcard.2024.131819_bb0115","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ijcard.2022.05.052","article-title":"Novel multiple sclerosis agents-associated cardiotoxicity: a real-world pharmacovigilance study","volume":"362","author":"Al-Yafeai","year":"2022","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2024.131819_bb0120","unstructured":"Cardiovascular complications of modern multiple myeloma therapy: A pharmacovigilance study - Al-Yafeai - 2023 - British Journal of Clinical Pharmacology - Wiley Online Library. 2024. https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/abs\/10.1111\/bcp.154991 (accessed 29 August 2023)."},{"key":"10.1016\/j.ijcard.2024.131819_bb0125","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/pds.3979","article-title":"Completeness of serious adverse drug event reports received by the US Food and Drug Administration in 2014","volume":"25","author":"Moore","year":"2016","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.ijcard.2024.131819_bb0130","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1080\/14740338.2017.1323867","article-title":"Empirical estimation of under-reporting in the U.S. Food and Drug Administration adverse event reporting system (FAERS)","volume":"16","author":"Alatawi","year":"2017","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.ijcard.2024.131819_bb0135","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1007\/s13555-023-00987-z","article-title":"Circadian oscillations of minimal erythema dose (MED) are also influenced by diet in patients with psoriasis: a Chronomedical study","volume":"13","author":"Damiani","year":"2023","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.ijcard.2024.131819_bb0140","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1007\/s13555-023-00986-0","article-title":"The prevalent Comorbidome at the onset of psoriasis diagnosis","volume":"13","author":"Buja","year":"2023","journal-title":"Dermatol. Ther."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527324001840?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527324001840?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T21:04:09Z","timestamp":1759093449000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527324001840"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":26,"alternative-id":["S0167527324001840"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2024.131819","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel anti-psoriasis agent-associated cardiotoxicity, analysis of the FDA adverse event reporting system (FAERS)","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2024.131819","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"131819"}}